Compare BioNTech SE - ADR (BNTX) vs Carvana Co (CVNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Carvana Co — how do they compare? BioNTech SE - ADR trades at $93.06 (market cap $23.31B), while Carvana Co trades at $71.58 (market cap $79.17B). The key difference: Carvana Co is far larger — about 3.4× BioNTech SE - ADR's market cap, and Carvana Co is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | CVNA | |
|---|---|---|
Market Cap | $23.31B | $79.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $95.69 |
52-Week Low | $83.89 | $56.27 |
Enterprise Value | $6.60B | $81.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.27, up 0.51% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q2 2026 revenue of $106 million, missing expectations, and lowered its full-year sales outlook due to weak COVID-19 vaccine demand. Despite negative net income margins and cash outflows, BNTX maintains a strong cash position of $16.78 billion and is advancing its oncology pipeline with 14 pivotal clinical trials.
The outlook is mixed: analyst consensus is strongly bullish with a $121 price target, but declining COVID revenue and ongoing losses pose significant risks. Investment opportunity hinges on successful pipeline development, while near-term headwinds from vaccine demand softness and leadership transition require careful monitoring.
Carvana (CVNA) trades at $70.83, down 4.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported record Q2 2026 results with revenue up 52% year-over-year to $7.38 billion and net income of $513 million, though shares fell due to disappointing full-year EBITDA guidance. Strong cash flow generation continues with 2025 operating cash flow of $1.04 billion.
Outlook remains positive with analyst consensus price target of $87.18 implying 23% upside, but execution risks and premium valuation (P/E 38.1) temper enthusiasm. Key risks include profit margin compression and high debt levels despite improving leverage ratios. The stock faces near-term pressure from guidance concerns but maintains long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →
